Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

EHA-LSHBT Virtual Hematology Updates, a Successful Course Tailored for the Region!

March – October 2021

In a series of six webinar courses chairs Gianluca Gaidano (EHA) and Ali Taher (LSHBT) were joined by several experts that gave lectures and interactive patient cases to practitioners who manage patients with benign and hematologic malignancies.…

Read more

More than science: the European Affairs program at EHA2023

To develop and administer safe, innovative and effective treatments for patients with blood diseases, hematologists need an effective and enabling regulatory environment.

Read more

Scientific networks

Specialized Working Groups (SWGs)In order to cover the full hematology field, EHA Specialized Working Groups (SWGs) are divided in two groups: disease-oriented and overarching SWGs.

Read more

EHA Research Conference 2025

Dates: March 17-20, 2025
Location: Málaga, Spain
Chairs: Alba Maiques Diaz, Ruud Delwel, Panagiotis Ntziachristos, Marcus Buschbeck, Mark Dawson, 
Özgen Deniz, Kimberly Stegmaier, and Nina Cabezas Wallscheid

Registration is now open

EHA is proud to announce the third edition of the EHA Research Conference, titled "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis".…

Read more